CONSULTANT PHARMACIST最新文献_第8页

Effects of Denosumab After Treatment Discontinuation : A Review of the Literature. Denosumab停药后的疗效:文献综述。

CONSULTANT PHARMACIST Pub Date : 2018-03-01 DOI: 10.4140/TCP.n.2018.142

Maryam Iranikhah, Crystal Deas, Pilar Murphy, Maisha Kelly Freeman

{"title":"Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.","authors":"Maryam Iranikhah, Crystal Deas, Pilar Murphy, Maisha Kelly Freeman","doi":"10.4140/TCP.n.2018.142","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.142","url":null,"abstract":"Objective: To review and summarize studies on the effects of denosumab on bone mineral density following the discontinuation of therapy.Data sources: A search of PubMed (1966-July 2017) and International Pharmaceutical Abstracts (1970-July 2017) was conducted using the Medical Subject Headings (MeSH) terms denosumab, osteoporosis, and withholding treatment in combination with free term searches including the words drug holiday, discontinue, discontin*, and drug discontinuation.Study selection and data extraction: An initial review yielded 10 articles. Four articles that addressed the effects of denosumab discontinuation on markers of overall bone health, fracture risk, or bone histology were included in the final review.Data synthesis: Denosumab is a monoclonal antibody indicated for the treatment of osteoporosis in men and postmenopausal women. Denosumab has proven beneficial effects on bone remodeling and bone mineral density, and these effects have been noted to be reversed upon treatment discontinuation because of the agent's lack of incorporation into bone matrix. After 12 to 24 months off denosumab therapy, BMD, BTMs levels, as well as histologic and histomorphometric analyses, were reflective of baseline values. The number of studies evaluating the residual skeletal effects of denosumab is limited, and the sample sizes in the articles reviewed were relatively small.Conclusion: An evaluation of studies showed that the discontinuation of denosumab results in loss of bone mineral density and a decline to near baseline values within 12 months of discontinuing therapy. Larger extension studies in a more diverse population need to be conducted to extrapolate the data to other patient groups.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36065145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

The Medicare Part D Season Begins, Again. 医疗保险D部分又开始了。

CONSULTANT PHARMACIST Pub Date : 2018-03-01 DOI: 10.4140/TCP.n.2018.172

Paul Baldwin

引用次数: 0

Gaps in OTC Labeling: Potentially Inappropriate Medications for Older Adults. OTC标签的空白:可能不适合老年人的药物。

CONSULTANT PHARMACIST Pub Date : 2018-03-01 DOI: 10.4140/TCP.n.2018.159

Archana Raghavan, Yoshita Paliwal, Patricia W Slattum

引用次数: 2

Assessing Pneumococcal Vaccination Availability in Under-Vaccinated Rural Counties: A Pharmacy Perspective. 评估肺炎球菌疫苗接种不足的农村县的可用性:药房的观点。

CONSULTANT PHARMACIST Pub Date : 2018-03-01 DOI: 10.4140/TCP.n.2018.163

Karen Colorafi, Shannon Panther, Kimberly McKeirnan, Daryl Potyk, John McCarthy, Sarah Temple

{"title":"Assessing Pneumococcal Vaccination Availability in Under-Vaccinated Rural Counties: A Pharmacy Perspective.","authors":"Karen Colorafi, Shannon Panther, Kimberly McKeirnan, Daryl Potyk, John McCarthy, Sarah Temple","doi":"10.4140/TCP.n.2018.163","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.163","url":null,"abstract":"Objective: Vaccines are a low-cost, high-impact interventions that effectively and efficiently reduce the burden of infectious diseases. Many rural populations have vaccination rates well below nationally recommended levels. Community pharmacies may offer a solution to this problem. Under a collaborative drug therapy agreement (CDTA), pharmacists can prescribe and administer immunizations. The purpose of this study was to examine pneumococcal vaccine access in rural pharmacies in Eastern Washington state.Design: A qualitative descriptive design was utilized in this study. The sample included all pharmacies located in two rural Washington state counties. Interviews were conducted with pharmacy staff. Every pharmacy in the two counties was surveyed over the telephone. Data analysis included directed content analysis and descriptive statistics.Findings: Each of the 10 pharmacies identified participated. Pharmacy volume varied (weekly prescription counts of 300 to 2,500). Sixty percent of pharmacies currently provide vaccines. Quoted prices of the PCV13 varied between $65 and $228. Quoted prices of the PPSV23 varied between $64 and $120. Pharmacies that vaccinated made it convenient with \"walk-in\" scheduling practices. Some pharmacies required a prescription from a separate provider while others could prescribe on-site through CDTA. Pharmacies that chose not to vaccinate did so for a variety of reasons.Conclusions: Access to pneumococcal vaccines will be enhanced by pharmacist administration, resulting in improved availability, accessibility, accommodation, affordability, and acceptability for patients in rural Washington.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36064069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Proper Antibiotic Use in a Home-Based Primary Care Population Treated for Urinary Tract Infections. 以家庭为基础的初级保健人群治疗尿路感染时抗生素的正确使用。

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.105

Megan E Gee, James Ford, Erin L Conway, Michael C Ott, John A Sellick, Kari A Mergenhagen

{"title":"Proper Antibiotic Use in a Home-Based Primary Care Population Treated for Urinary Tract Infections.","authors":"Megan E Gee, James Ford, Erin L Conway, Michael C Ott, John A Sellick, Kari A Mergenhagen","doi":"10.4140/TCP.n.2018.105","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.105","url":null,"abstract":"Objective: To evaluate the trends associated with diagnosis and treatment of urinary tract infections (UTI) in a home-based primary care population of Veterans Health System patients from 2006 to 2015.Design: Retrospective cohort study.Setting: Veterans Healthcare System.Participants: Home-based primary care patients treated for UTI from 2006 to 2015.Interventions: None.Main outcome measure: Appropriate therapy was determined based on the McGeer criteria. Multivariate logistic regression was used to determine factors leading to appropriate UTI treatment.Results: Of 366 available patients, 68 (18.6%) were tested for a UTI. Appropriate therapy occurred in 26% of patients. Allergy to any antibiotic increased the odds of appropriate treatment (odds ratio [OR] = 5.6, 95% confidence interval [CI] 1.5-23.2). Flank pain and increased urinary frequency also increased the likelihood of being treated appropriately (OR = 25.9, 95% CI 2.9-584.0 and OR = 4.49, 95% CI 0.99-21.2, respectively).Conclusion: Antibiotics were overused for treating UTIs in the homebound population. Patients with flank pain, increased urinary frequency, and antibiotic allergy were more likely to receive appropriate treatment. Pharmacists, therefore, have a viable opportunity to increase appropriate antibiotic prescribing in the home-based primary care population.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35801985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Medical-Legal Partnerships: A Healing Collaboration. 医疗-法律伙伴关系:治愈合作。

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.66

Caroline J Wick, Jeannette Y Wick

{"title":"Medical-Legal Partnerships: A Healing Collaboration.","authors":"Caroline J Wick, Jeannette Y Wick","doi":"10.4140/TCP.n.2018.66","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.66","url":null,"abstract":"Medical providers know that there are some conditions they can't treat because the condition is caused or exacerbated by social conditions and are known as \"social determinants of health.\" ThIs classic example-a patient has asthma, lives in a moldor cockroach-infested apartment, has no resources to move, and has a landlord who refuses to clean or exterminate bugs- exemplifies why patients need legal advocates to improve their health. This article discusses medical-legal partnerships (MLPs), models in which medical providers refer patients to attorneys to represent them to resolve such problems. MLPs recognize social determinants of health and foster collaboration between attorneys and health care providers. Originally developed to advocate for children, many MLPs now focus on the vulnerable elderly, individuals at the end of life, and veterans. As these collaborations grow, it's important to spread the word among health care providers and to engage all collaborators. Today, more than 300 MLPs across the nation have documented remarkable achievements. The authors hope that in the future, pharmacists will become MLP team members and help patients address many of their medication-related problems.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.66","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35800630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resolve to Be Better. 决心做得更好。

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.58

H Edward Davidson

引用次数: 0

Bezlotoxumab for the Prevention of Clostridium difficile Recurrence. 贝佐单抗预防艰难梭菌复发。

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.89

Elias B Chahine, Jonathan C Cho, Marylee V Worley

{"title":"Bezlotoxumab for the Prevention of Clostridium difficile Recurrence.","authors":"Elias B Chahine, Jonathan C Cho, Marylee V Worley","doi":"10.4140/TCP.n.2018.89","DOIUrl":"https://doi.org/10.4140/TCP.n.2018.89","url":null,"abstract":"Objective: To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and administration of bezlotoxumab (BEZ), as well as its place in the prevention of Clostridium difficile infection (CDI) recurrence.Data sources: A search of PubMed and Google Scholar using the terms \"bezlotoxumab,\" \"CDB1,\" \"MDX-1388,\" and \"MK-6072\" was performed. The manufacturer's website was also reviewed to further identify relevant information.Study selction: All English-language articles from 2006 to May 2017 appearing in these searches were reviewed for relevance to this paper. In addition, their bibliographies were reviewed to identify any articles not identified in the searches.Data synthesis: BEZ is a human monoclonal antibody that binds to Clostridium difficile toxin B. It is approved by the Food and Drug Administration to reduce CDI recurrence in adult patients who are receiving antibiotic therapy for CDI and are at high risk for CDI recurrence. It is given as a single dose of 10 mg/kg via an intravenous infusion. It is eliminated by catabolism. Phase III clinical trials demonstrated that BEZ was associated with significantly lower rates of CDI recurrence, compared with placebo. The most common adverse events reported during clinical trials were diarrhea and nausea. There is a warning regarding the use of BEZ in patients with a history of congestive heart failure. The most common adverse reactions associated with BEZ are nausea, pyrexia, and headache.Conclusion: BEZ has been proven safe and effective in preventing CDI recurrence. Given its high cost, it should be reserved for patients at high risk for CDI recurrence.","PeriodicalId":45985,"journal":{"name":"CONSULTANT PHARMACIST","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4140/TCP.n.2018.89","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35801984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Naloxone for Opioid Overdose and the Role of the Pharmacist. 纳洛酮治疗阿片类药物过量及药师的作用。

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.98

Yuliana Toderika, Shalonda Williams

引用次数: 14

What's Ahead for Health Care in 2018. 2018年医疗保健的前景如何?

CONSULTANT PHARMACIST Pub Date : 2018-02-01 DOI: 10.4140/TCP.n.2018.116

Paul Baldwin

引用次数: 0